Journal of Nuclear Medicine

Papers
(The H4-Index of Journal of Nuclear Medicine is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Practicing Medicine in Wartime Ukraine212
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression155
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States124
CCK2Receptor Ligand [68Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [68Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer124
Positron Range Correction Helps Enhance the Image Quality of Cardiac82Rb PET/CT118
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study113
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer110
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions109
Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities101
68Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines95
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of99mTc and188Re Theranostic Agents for Prostate Cancer93
Interspecies Variability in Biodistribution and PET Imaging Performance of [18F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer90
State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging84
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [18F]PSMA-1007 PET/CT84
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green83
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer79
Serial [18F]AlF-NOTA-FAPI PET/CT and CT Angiography in Type B Aortic Dissection Before and After Thoracic Endovascular Aortic Repair76
Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls71
Impact of Single-Time-Point Estimates of177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles71
Combined PARP1-Targeted Nuclear Contrast and Reflectance Contrast Enhance Confocal Microscopic Detection of Basal Cell Carcinoma71
[177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial66
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study64
Preclinical Evaluation of226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy64
Quantitative Deauville Scoring to Uncover Prognostic Information from 18F-FDG PET–Based Response Assessment: Data from the EuroNet-PHL-C1 Trial59
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals58
Localized In Vivo Prodrug Activation Using Radionuclides56
177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial55
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [15O]H2O PET Imaging54
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma54
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)53
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 252
First-in-Human Study of [11C]NCGG401 for Imaging Colony-Stimulating Factor 1 Receptors in the Brain52
Challenges with177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice51
161Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with177Lu in Preclinical Models of Ovarian Cancer50
Biodistribution, Safety Profile, and Radiation Dosimetry of [18F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects50
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care49
The Role of Molecular Imaging in Precision Oncology48
Funding Reductions Threaten the Future of Medical Innovation48
Preclinical Characterization of the Tau PET Tracer [18F]SNFT-1: Comparison of Tau PET Tracers48
Reply to “Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals”45
Early-Phase18F-Florbetapir and18F-Flutemetamol Images as Proxies of Brain Metabolism in a Memory Clinic Setting45
18F-FDG PET in Myocardial Viability Assessment: A Practical and Time-Efficient Protocol45
Single Chelator–Minibody Theranostic Agents for89Zr PET Imaging and177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer44
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses44
0.039708137512207